Prognostic Biomarkers for Melanoma Immunotherapy.

Prognostic Biomarkers for Melanoma Immunotherapy.

Publication date: Feb 11, 2020

Recent developments in immunotherapy have transformed the landscape of melanoma therapy. Here, we review markers for response to immunotherapy.

Current immunotherapies disable immune checkpoints on T cells and other immune cells and allow immune rejection of tumor. This process depends crucially on a preexisting response to the development of the melanoma. Here we describe the complexity of the anti-tumor immune response and the links to the development of markers that are currently used or under investigation in the clinic. We describe immune response biomarkers along with new developments that could translate into advances.

Twitty, C.G., Huppert, L.A., and Daud, A.I. Prognostic Biomarkers for Melanoma Immunotherapy. 25781. 2020 Curr Oncol Rep (22):3.

Concepts Keywords
Biomarkers Melanoma therapy
Immune Rejection Melanoma
Immunotherapies Landscape melanoma
Immunotherapy Immunotherapy
Melanoma Immunotherapies
Tumor Medicine
Clinical medicine
Immune system
Medical specialties
Cancer treatments
Immune checkpoint
Checkpoint inhibitor
Tumor microenvironment


Type Source Name
disease MESH Melanoma
pathway KEGG Melanoma
disease MESH tumor
disease MESH development
disease MESH death


Original Article

Leave a Comment

Your email address will not be published. Required fields are marked *